Impact of a Value-Based Formulary in Three Chronic Disease Cohorts

Research presented by Kai Yeung, PharmD, PhD, scientific investigator I, Group Health Research Institute, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.

Related Videos

Related Content

Advertisement

March 12th 2025

Frailty, Housing Instability Drive Mortality Risk in People With HIV

Brooke McCormick

These posters highlight the compounded challenges people with HIV face.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

March 12th 2025

VBID, Heading Into a Third Decade, Looks to Promote Personalization and Access

Christina Mattina

Speakers at the 2025 Value-Based Insurance Design summit recapped the accomplishments made over the past 20 years in designing insurance benefits with value in mind and looked ahead to iterations to come.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

March 12th 2025

Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH

Maggie L. Shaw Amy Colson, MD, MPH

New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.

March 12th 2025

Implementation, Adherence to DoxyPEP Remains Low in At-Risk Groups

Julia Bonavitacola

Patients in Washington D.C. and San Francisco had minimal early uptake and adherence to doxycycline post-exposure prophylaxis (DoxyPEP) in studies presented at the Conference on Retroviruses and Opportunistic Infections 2025.

Related Content

Advertisement

March 12th 2025

Frailty, Housing Instability Drive Mortality Risk in People With HIV

Brooke McCormick

These posters highlight the compounded challenges people with HIV face.

October 24th 2024

Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.

March 12th 2025

VBID, Heading Into a Third Decade, Looks to Promote Personalization and Access

Christina Mattina

Speakers at the 2025 Value-Based Insurance Design summit recapped the accomplishments made over the past 20 years in designing insurance benefits with value in mind and looked ahead to iterations to come.

April 25th 2024

Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.

March 12th 2025

Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH

Maggie L. Shaw Amy Colson, MD, MPH

New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.

March 12th 2025

Implementation, Adherence to DoxyPEP Remains Low in At-Risk Groups

Julia Bonavitacola

Patients in Washington D.C. and San Francisco had minimal early uptake and adherence to doxycycline post-exposure prophylaxis (DoxyPEP) in studies presented at the Conference on Retroviruses and Opportunistic Infections 2025.